Goodwin Procter LLP advised SpringWorks Therapeutics on the deal. SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced its asset purchase and exclusive license agreement under which Jazz Pharmaceuticals…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
